Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment... On Wednesday ...

Gainers: NATR +26%. AKBA +17%. ELMD +9%. SYRS +9%. NEPT +8%.Losers: ETRM -25%. MIRN -23%. IMUC -18%. PTX -17%. BVX -17%.Now read: Biotech Forum Daily Digest: Citron ...

Short interest in Syros Pharmaceuticals Inc (NASDAQ:SYRS) decreased during the last reporting period, falling from 999.93K to 952.60K. This put 3.87% of the company's publicly available shares short.

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...